NASDAQ · INMD
InMode Ltd.
Healthcare · Medical - Devices
$13.97▼ 0.57% ($0.08)at close
As of 4:00 PM ET
Valuation
Revenue & margin DCF
Verdict: cheap. Price below all scenarios.
The price holds with revenue shrinking 5.9% a year for 10 years. Our scenarios assume 0.6–4.4%.
That's below its past 4-year pace of 0.9%.
Value per share
Base case
$16.48
Price used $13.97 is 15% below this
USD · TTM ending Jun 30, 2026 · Price Oct 23, 8:00 PM UTC
Revenue each value needs
Revenue today $375M. The price needs $203M by 2036. Base case: $406M. At its recent pace: $409M. Bear to Bull: $398M to $576M.
Revenue today $375M. The price needs $203M by 2036. Base case: $406M. At its recent pace: $409M. Bear to Bull: $398M to $576M.
Revenue in 2036
today $375M
−$202Mless than the Base case
Value per share · Base case
$16.48
Price $13.97
15% below this
- 10-yr revenue CAGR
- 0.8%
- Ending operating margin
- 18.5%
- Discount rate
- 13.5%
USD · TTM ending Jun 30, 2026 · Price Oct 23, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 9.75% over the last year. Revenue declined 6.71% over the trailing twelve months. Operating margin moved from 28.54% to 18.47%. Free cash flow declined 16.05% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 18.47%. A decisive move in revenue — currently down 6.71% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States.
Market multiples
Stock splits
Every 1 shares became 2
Profitability & growth
Analyst consensus
5
Buy
6
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 11, 2026
Q3 FY26 · EPS est $0.32 · Revenue est $91.6M
Same quarter, year over year
FY26 YTD -23.1%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $0.60 vs $0.78 · 0 of 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
—
—
FY23
—
—
—
Fiscal year totals
- FY25
- $1.62
- —
Q2 FY26
Reported Aug 5, 2026 · Latest
HoverTap a cell to inspect
Actual
$0.35
Estimate
$0.35
Year over year
-25.5%
Vs prior quarter
+40.0%
Institutional Sentiment
InMode Ltd. · INMD
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.